Introduction {#section1-0022155415597738}
============

Diagnostic immunohistochemistry (IHC) is a technique stably embedded in the daily practice of human pathology worldwide. The vast majority of IHC tests are done on tissue which has been fixed in formalin, embedded in paraffin (FFPE), and stored at room temperature. The introduction of a heat-mediated process for the retrieval of the immune reactivity of the tissue (antigen retrieval; AR) ([@bibr48-0022155415597738]) has further consolidated this practice. Nowadays, IHC is the most versatile of the companion diagnostics needed for individualized therapy ([@bibr54-0022155415597738]).

The diagnostic use of IHC requires standardization by adoption of common analytical protocols (both pre-analytical and analytical) and quality control (QC) programs, as suggested by the College of American Pathologists ([@bibr19-0022155415597738]; [@bibr26-0022155415597738]; [@bibr28-0022155415597738]; [@bibr45-0022155415597738]). In Europe, at least two initiatives (NordicQC in Denmark and NEQAS in UK) run voluntary QC tests for IHC. QC tests are run on human tissue remnants from the operating theater, which are used as external control tissue samples; although, there are severe procurement and quality limitations for normal noble tissues such as brain, brainstem, heart, and some endocrine organs (pituitary, parathyroid). In addition, ethical considerations and nation-specific rules restrict the exchange of material across Europe ([@bibr44-0022155415597738]; [@bibr56-0022155415597738]).

Despite the widespread use of this technique, the most difficult task is to validate the staining in situ, given that a surprisingly high number of antibodies are not specific for the intended target ([@bibr4-0022155415597738]). At the beginning, immunizing an animal with a biochemically purified abundant antigen and staining with a relatively low-level sensitivity method was enough to produce results with acceptable specificity. However, the advent of the Human Genome project brought the need to produce specific antibodies against molecularly discovered antigen-carrying proteins, often expressed at low level and bearing sequence domains that are shared with other unrelated proteins.

The introduction of methods of synthetic peptide immunization with unique sequences from the desired protein as well as monoclonal antibody production effective in FFPE tissues ([@bibr31-0022155415597738]) has consolidated the presence of IHC in daily practice. Antibodies raised against synthetic peptides may recognize continuous epitopes in FFPE material ([@bibr31-0022155415597738]; [@bibr51-0022155415597738]). Indeed, indirect evidence from an analysis of rabbit antisera produced against recombinant sequences of 50--150 amino acids showed that target-specific components of antisera directed against linear epitopes correctly identifies denatured targets on a western blot, whereas those against conformational epitopes do not ([@bibr20-0022155415597738]).

Furthermore, the binding of anti-peptide antibodies may be inhibited through competition with the immunizing peptide. However, this does not guarantee specificity ([@bibr29-0022155415597738]), and specificity is therefore implied by a complex combination of indirect evidence ([@bibr3-0022155415597738]; [@bibr50-0022155415597738]). Then again, probing a knock-out experimental animal or employing a gene-silenced cell line, while the most stringent, are often impractical and costly solutions.

Ideally, one would need an identically processed tissue as that of the diagnostic human biopsy, which contains controlled and known variations of the antibody epitope and abundant similar background noise-producing bystander proteins to mimic the staining conditions in the human material. The use of an animal substitute for this task may represent a convenient solution for exploration. The extremely low probability that two unrelated but antigenically identical proteins may be represented in another species preserving the similarity of the unrelated sequences will make a differential immunostaining across the two species the evidence that the antibody is not recognizing an epitope uniquely identifying a protein. On the other hand, conserved proteins performing an identical function in related species may be found identically distributed and therefore similarly stained in the same tissues.

The domestic pig (*Sus scrofa*) is farmed across Europe for human consumption. Overall, the pig genome is 84.1% homologous to the human genome ([@bibr18-0022155415597738]), one of the closest taxa after the primates. The pig and human genomes diverged 97 million years ago; yet the porcine genome has extensive similarities with the human genome and, thus, it represents an interesting disease model ([@bibr27-0022155415597738]). About 250 genes were gained or lost in each species after divergence, most notably the interferon-associated genes and olfactory genes, among others ([@bibr18-0022155415597738]; [@bibr27-0022155415597738]). Genes conserved in the pig related to the cardiovascular function or drug response are the most studied.

The aim of this study was, therefore, to test human diagnostic antibodies on similar, but not identical, swine orthologous targets in order to understand how antibodies bind to FFPE tissue, as well as determine whether these are continuous linear or discontinuous epitopes, which are the epitope variations permissive for binding, and whether porcine tissue could be used for QC in IHC.

Materials & Methods {#section2-0022155415597738}
===================

Tissues and Ethics Statement {#section3-0022155415597738}
----------------------------

Mature, 8-month-old castrated pigs (*Sus scrofa domesticus*) and 10-year-old bulls *(Bos taurus*) were sacrificed in abattoirs certified by the local Health Authority (ASL).

Formalin-fixed, paraffin-embedded (FFPE) fully anonymous human leftover material is exempt from the San Gerardo Institutional Review Board (IRB) approval as per Hospital regulations (ASG-DA-050 Donazione di materiale biologico a scopo di ricerca e/o sperimentazione, May 2012).

The specimens were fixed overnight at room temperature in phosphate-buffered 10% formalin, pH 7.2--7.4 (Bio-Optica, Milano, Italy). The tissue was dehydrated through a graded alcohol series, transferred to D-limonene (Bioclear; Bio-Optica) and embedded in paraffin. Three-µm sections were cut and placed on positively charged glass slides, baked, deparaffinized in xylene, and then rehydrated through a graded alcohol series and brought to water until further use.

Selected specimens were snap-frozen, sectioned in a cryostat (Leica Microsystems, Milan, Italy) and acetone-fixed.

Routine immunostaining was performed along diagnostic runs on a modified pig "Multi-sausage" tissue block ([@bibr2-0022155415597738]) containing a human specimen relevant for the staining protocol as a control.

Immunohistochemistry (IHC) Protocols {#section4-0022155415597738}
------------------------------------

Inclusion criteria for antibodies were: i) performance on FFPE material, ii) directed at non-polymorphic antigens in the human, iii) relevant for diagnosis or research, and iv) well characterized in terms of specificity. Antibodies against human pathogens and gene mutation-specific were excluded.

Sections were stained as per individual antibody dilutions and protocols established in our laboratory for diagnostic human IHC on a Dako Autostainer Link 48 (Dako, Glostrup, Denmark) with established protocols as suggested by the manufacturer. None required retrieval with proteases.

For individual manual stains, see Supporting Information S1.

Surveys of the reactivity of antibodies raised against human antigens on swine tissue fixed by routine methods have been published previously ([@bibr5-0022155415597738]; [@bibr9-0022155415597738]; [@bibr12-0022155415597738]; [@bibr14-0022155415597738]; [@bibr16-0022155415597738]; [@bibr30-0022155415597738]; [@bibr35-0022155415597738]; [@bibr36-0022155415597738]; [@bibr49-0022155415597738]; [@bibr53-0022155415597738]).

Scoring Criteria {#section5-0022155415597738}
----------------

Results were scored for subcellular distribution (nuclear, cytoplasmic, membranous) and combinations of subcellular staining and intensity. In addition, the architectural distribution of the stained cells within structured tissues was noted (e.g., proliferating germinal centers versus mantle or interfollicular areas, basal cells in intestinal glands versus apical luminal cells, nerve cells and fibers within smooth muscle layers, among others).

A stain was scored positive if (1) the stain was qualitatively and quantitatively different from the occasional homogeneous faint and diffuse non-specific negative control staining; and (2) both the expected subcellular localization and the architectural distribution were maintained in the porcine tissue, compared with the reference human reactivity. For antigens ubiquitously expressed or known to have a tissue- or subunit-dependent variegation (e.g., S-100 ([@bibr52-0022155415597738])), putative taxonomic variations were accepted, if the subcellular distribution and at least some of the human pattern was maintained in the pig.

Sequence Retrieval and Alignment {#section6-0022155415597738}
--------------------------------

The epitope sequence, provided by the manufacturer or collected from the published literature, was used for the human--pig amino acid (aa) sequence comparison and is reported in [Table 1](#table1-0022155415597738){ref-type="table"}. In the absence of a known sequence, a 100--300-aa sequence was used if the epitope was generically listed as "C-" or "N-terminus". In the absence of either, the whole protein sequence was used. Only the shorter of these three choices was used for the analysis. Details and additional information is contained in Supporting Information Table S1.

###### 

Targeted Proteins, Antibodies Used, Sequences, Similarity and Results.

![](10.1369_0022155415597738-table1)

  Target                                    Source   Antibody        Clone          Epitope                                              UNIPROT Human   UNIPROT Swine   Similarity Hu/Sw   Tested                                                        Class
  ----------------------------------------- -------- --------------- -------------- ---------------------------------------------------- --------------- --------------- ------------------ ------------------------------------------------------------- -------------------------------
  Actin, alpha skeletal muscle              11       IgG1            HHF35          unknown                                              P68133          P68137          100%               POS                                                           Basic cytoskeletal
  Actin, aortic smooth muscle               5        IgG2a           1A4            10 N-term aa                                         P62736          C7AI81          100%               POS                                                           Basic cytoskeletal
  ALK (CD246)                               4        Rb mAb          D5F3           C-term (cytoplasmic dom. aa 1060--1620)              Q9UM73          K7GQT6          83%                NEG                                                           Receptor signaling
  ALK (anaplastic lymphoma kinase; CD246)   5        IgG3            ALK1           aa 1359--1460 (419--520 chimera)                     Q9UM73          K7GQT6          83%                NEG                                                           Receptor signaling
  ALK (CD246)                               9        IgG1            5A4            aa 419--520 (chimera)                                Q9UM73          K7GQT6          99%                NEG                                                           Receptor signaling
  ALK (CD246)                               11       Rb mAb          SP8            tyrosine kinase catalytic domain & C-terminus        Q9UM73          K7GQT6          91%                NEG                                                           Receptor signaling
  AMACR                                     5        Rb mAb          13H4           unknown                                              Q9UHK6          F1SP14          78%                NEG                                                           Cytoplasmic; misc
  BCL-2                                     5        IgG1            Bcl-2-100      aa 41--54                                            P10415          A5A790          100%               POS                                                           Apoptosis-related
  BCL6                                      5        IgG1            PG-B6p         aa 3--484                                            P41182          F1FSH8          93%                NEG                                                           TF
  BCL6                                      6        IgG2b           LN22           aa 1--350                                            P41182          F1FSH8          93%                POS                                                           TF
  BCL6                                      9        Rb poly         BCL6 (N3)      aa 3--484                                            P41182          F1FSH8          93%                POS                                                           TF
  BRCA-1                                    7        IgG1            MS110          aa 1--304                                            Q3B891          A5A751          82%                NEG                                                           Cell cycle; DNA replication
  CA125                                     5        IgG1            M11            unknown                                              N/A             N/A             N/A                NEG                                                           Cell--cell interaction
  Calcitonin                                5        Rb poly                        unknown                                              P01258          A6P7L6          61%                POS                                                           Cytoplasmic; misc
  Calponin 2                                5        IgG1            CALP           unknown                                              Q99439          Q08094          92%                POS                                                           Basic cytoskeletal
  Calretinin                                5        IgG1            DAK-Calret 1   unknown                                              P22676          F1S3E7          97%                NEG                                                           Cytoplasmic; misc
  CCND1 (Cyclin D1)                         11       Rb mAb          SP4            C-term (100 aa)                                      P24385          F1RY77          98%                NEG                                                           Cell cycle; DNA replication
  CD10                                      5        IgG1            56C6           external domain (52--750)                            P08473          K7GMJ2          94%                POS                                                           Receptor signaling
  CD117 (c-kit)                             5        Rb poly                        aa 963--976 (C-term)                                 P10721          Q2HWD6          90%                POS                                                           Receptor signaling
  CD138                                     5        IgG1            MI15           ectodomain (aa 105--112)                             P18827          M5DFN4          77%                NEG                                                           Cell--cell interaction
  CD14                                      10       Rb poly         HPA002127      aa 229--370                                          P08571          A2SW51          72%                NEG                                                           Cell--cell interaction
  CD141                                     1        Rb mAb          EPR4051        C-term (150 aa)                                      P07204          B3STX8          69%                NEG                                                           Receptor signaling
  CD15                                      5        IgM             C3D-1          Lewis-X                                              N/A             N/A             N/A                NEG                                                           Cell--cell interaction
  CD16                                      6        IgG2a           2H7            External domain (aa 17--208)                         P08637          Q28942          60%                NEG                                                           Cell--cell interaction
  CD16                                      9        IgG1            DJ130c         unknown                                              P08637          Q28942          63%                NEG                                                           Cell--cell interaction
  CD163                                     11       IgG1            10D6           Domain 1--4 (N-term)                                 Q86VB7          Q28942          90%                NEG                                                           Cell--cell interaction
  CD163L1                                   9        Rb mAb          EPR6539        Intracellular                                        Q9NR16          J9T9K7          55%                NEG                                                           Cell--cell interaction
  CD1a                                      5        IgG1            O10            unknown                                              P06126          A0ZPR3          63%                NEG                                                           Cell--cell interaction; Immun
  CD2                                       11       IgG1            TS2/18         unknown                                              P06729          F1SAX9          60%                NEG                                                           Cell--cell interaction; Immun
  CD20                                      5        IgG2a           L26            Intracellular (aa 1--56; aa 106--120; aa 210--297)   P11836          I3LDX9          73%                NEG                                                           Cell--cell interaction; Immun
  CD23                                      5        IgG1            DAK-CD23       aa 48--248                                           P06734          B8YM31          64%                NEG                                                           Cell--cell interaction; Immun
  CD271 (NGF-R p75)                         1        Rb mAb          EP1039Y        unknown                                              P08138          F1RVT6          72%                POS                                                           Receptor signaling
  CD3 epsilon                               5        Rb poly         poly           aa 156--168                                          P07766          P79264          92%                POS                                                           Cell--cell interaction; Immun
  CD30                                      5        IgG1            Ber-H2         unknown                                              P28908          F1RF73          58%                NEG                                                           Receptor signaling
  CD31                                      5        IgG1            JC70A          unknown                                              P16284          Q95242          58%                NEG                                                           Cell--cell interaction
  CD34                                      1        Rb mAb          EP373Y         C-term (100 aa)                                      P28906          K7GKN6          93%                NEG                                                           Cell---cell interaction
  CD34                                      5        IgG1            QBEnd10        Class II CD34                                        P28906          K7GKN6          63%                NEG                                                           Cell--cell interaction
  CD4                                       6        IgG1            1F6            External domain                                      P01730          Q6R3N4          59%                NEG                                                           Cell--cell interaction; Immun
  CD43                                      5        IgG1            DF-T1          unknown                                              P16150          D9MNC9          50%                NEG                                                           Cell--cell interaction
  CD44                                      10       Rb poly                        aa 176--313                                          P16070          F1SGT4          55%                NEG                                                           Cell--cell interaction
  CD45                                      5        IgG1            PD726 + 2B11   multiple                                             P08575          Q6SZ85          43%                NEG                                                           Receptor signaling
  CD45                                      9        IgG1            Bra-55         Extracellular (aa 24--575)                           P08575          Q6SZ85          20%                NEG                                                           Receptor signaling
  CD5                                       5        IgG1            4C7            External domain aa 25--372                           P06127          F1RIA2          62%                NEG                                                           Cell--cell interaction; Immun
  CD5                                       5        IgG1            CD5/54/F6      aa 474--495                                          P06127          F1RIA2          91%                POS                                                           Cell--cell interaction; Immun
  CD56                                      5        IgG1            123C3.D5       unknown                                              P13591          K7GMV4          97%                POS                                                           Cell--cell interaction
  CD57                                      5        IgM             TB01           unknown                                              Q96E93          F1SLW9          70%                POS^[\*](#table-fn1-0022155415597738){ref-type="table-fn"}^   Cell--cell interaction
  CD68                                      5        IgG1            KP1            unknown                                              P34810          F1S4M0          72%                NEG                                                           Cytoplasmic; misc
  CD68                                      5        IgG3            PGM1           unknown                                              P34810          F1S4M0          69%                NEG                                                           Cytoplasmic; misc
  CD68                                      9        Rb poly         CD68 (H-255)   aa 100--354                                          P34810          F1S4M0          69%                POS                                                           Cytoplasmic; misc
  CD7                                       11       IgG1            MEM-186        unknown                                              P09564          M5DNE0          47%                NEG                                                           Cell--cell interaction; Immun
  CD79a                                     5        IgG1            JCB117         Extracellular (aa 33--143\^)                         P11912          K7GM80          93%                POS (subpop)                                                  Cell--cell interaction; Immun
  CD79a                                     10       IgG1            HM47           aa 208--222                                          P11912          K7GM80          93%                POS                                                           Cell--cell interaction; Immun
  CD8 alpha                                 5        IgG1            C8/144B        13 C-term aa                                         P01732          F1SVD3          59%                NEG                                                           Cell--cell interaction; Immun
  CD99 (HBA 71)                             5        IgG1            12E7           unknown                                              P14209          F1RQ20          37%                NEG                                                           Cell--cell interaction
  CDKN1A (p21)                              11       IgG2b           CP74           aa 1--80                                             P38936          I3LK35          83%                NEG                                                           Cell cycle; DNA replication
  CDKN1B (p27)                              11       IgG1            DCS-72.F6      aa 83--204                                           P46527          I3LIR2          81%                POS                                                           Cell cycle; DNA replication
  CDKN1B (p27)                              11       Rb poly                        C-term (100 aa)                                      P46527          I3LIR2          86%                POS^[\#](#table-fn1-0022155415597738){ref-type="table-fn"}^   Cell cycle; DNA replication
  CDKN2A (p16)                              9        IgG2a           F-12           unknown                                              P42771          Q9TSY1          55%                NEG                                                           Cell cycle; DNA replication
  CDKN2A (p16)                              9        IgG2a           JC8            unknown                                              P42771          Q9TSY1          55%                NEG                                                           Cell cycle; DNA replication
  CDX2                                      1        IgG1            CDX2-88        unknown                                              Q99626          D0V4H7          96%                POS                                                           TF
  CEA                                       5        IgG1            II-7           unknown                                              P06731          K7GKS4          66%                NEG                                                           Cell--cell interaction
  CFTR                                      9        IgG1            M3A7           aa 1370--1380                                        P13569          Q6PQZ2          91%                NEG                                                           Receptor signaling
  Chromogranin A                            5        IgG2b           DAK-A3         aa 210--439                                          P10645          F1SD66          72%                POS                                                           Cytoplasmic; misc
  Cleaved Caspase 3                         4        Rb poly         Asp175                                                              P42574          Q95ND5          90%                POS                                                           Apoptosis-related
  Cleaved Caspase 3                         4        Rb mAb          5A1E                                                                P42574          Q95ND5          90%                POS                                                           Apoptosis-related
  Cleaved Notch                             4        Rb mAb          D3B8           Val1744                                              P46531          F1SB08          50%                NEG                                                           TF
  Cleaved Notch                             4        Rb poly                        Val1744                                              P46531          F1SB08          50%                NEG                                                           TF
  Cleaved PARP                              4        Rb mAb          D64E10         Asp214                                               P09874          I3LDH3          94%                NEG                                                           TF
  CTNNB1                                    2        IgG1            \#14           aa 571--781 (mouse)                                  B4DGU4          Q8WNW4          99%                POS                                                           Cell--cell interaction
  Cytokeratin-A 34BETA E12                  5        IgG1            34bE12         Ker 1, 5, 10, 14                                     N/A             N/A             N/A                POS                                                           Basic cytoskeletal
  Cytokeratins AE1-AE3                      5        IgG1 (pooled)   AE1-AE3        multiple                                             N/A             N/A             N/A                POS                                                           Basic cytoskeletal
  Cytokeratins 5/6                          5        IgG1            D5/16 B4       unknown                                              N/A             N/A             N/A                POS                                                           Basic cytoskeletal
  Cytokeratins 8/18                         11       IgG2a           5D3            unknown                                              N/A             N/A             N/A                NEG                                                           Basic cytoskeletal
  Desmin                                    11       IgG1            D33            unknown                                              P17661          P02540          98%                POS                                                           Basic cytoskeletal
  E-Cadherin                                5        IgG1            NCH-38         unknown                                              P12830          C6EVT4          84%                POS                                                           Cell--cell interaction
  E2-2/TCF4                                 10       IgG2a           6H5-3          aa 31--331                                           P15884          F1S1Z1          99%                POS                                                           TF
  E2A/E47/TCF3                              10       Rb poly         N-649          aa 1--649                                            P15923          F1SDI1          71%                NEG                                                           TF
  EMA                                       5        IgG2a           E29            APDTRP repeat on Mucin-1                             P15941          F1RGR9          40%                POS^[¥](#table-fn1-0022155415597738){ref-type="table-fn"}^    Cell--cell interaction
  Emerin                                    9        Rb poly         (FL-254)       aa 3--254                                            P50402          I3LHY0          50%                POS                                                           Cell cycle; DNA replication
  ER alpha                                  5        IgG1            1D5            N-term (aa 24--575)                                  P03372          Q29040          92%                POS                                                           TF
  Foxp3                                     1        IgG1            236A/E7        unknown                                              Q9BZS1          Q6BBQ1          90%                NEG                                                           TF
  FRMD6                                     10       Rb poly                        unknown                                              Q96NE9-3        F1SFF5          96%                POS                                                           Cell--cell interaction
  GFAP                                      5        Rb poly                        unknown                                              P14136          F1RR02          93%                POS                                                           Basic cytoskeletal
  gH2AX                                     4        Rb mAb                         phospho-epitope                                      N/A             N/A             N/A                POS                                                           Apoptosis-related
  gH2AX                                     7        IgG1            JBW301         phospho-epitope                                      N/A             N/A             N/A                POS                                                           Apoptosis-related
  HER2/ErbB2                                5        Rb poly                        unknown                                              P04626          K7GS43          91%                NEG                                                           Receptor signaling
  HER2/ErbB2                                11       IgG1            e2-4001        intracellular (aa 676--1255)                         P04626          K7GS43          94%                NEG                                                           Receptor signaling
  HER2/ErbB2                                11       Rb mAb          SP3            extracellular (aa 23--652)                           P04626          K7GS43          89%                NEG                                                           Receptor signaling
  HTR2B                                     10       Rb poly                        aa 240--326                                          P41595          F1SMV8          91%                POS                                                           Receptor signaling
  ID1                                       3        Rb mAb          BCH-1/195-14   unknown                                              P41134          B3W6M6          91%                NEG                                                           TF
  ID2                                       3        Rb mAb          BCH-3/9-2-8    unknown                                              Q02363          Q2VIU1          98%                POS                                                           TF
  ID3                                       3        Rb mAb          BCH-4/17-3     unknown                                              Q02535          B3W6M8          96%                NEG                                                           TF
  Inhibin alpha                             5        IgG2a           R1             aa 1--32                                             P05111          P04087          83%                POS                                                           Cytoplasmic; misc
  IRF4                                      1        Rb mAb          EP5699         unknown                                              Q15306          A0MZ86          93%                POS                                                           TF
  IRF8                                      10       Rb poly                        aa 90--211                                           Q02556          Q6T5D3          88%                POS                                                           TF
  Ki-67                                     5        IgG1            MIB 1          aa 1101--1112 (FKELF)                                P46013          I3LNN3          40%                POS                                                           Cell cycle; DNA replication
  Ki-67                                     8        IgG2a           UMAB107        aa 1160--1493                                        P46013          I3LNN3          45%                POS                                                           Cell cycle; DNA replication
  Ki-67                                     11       Rb mAb          SP6            C-term (150 aa)                                      P46013          I3LNN3          92%                NEG^[\#](#table-fn1-0022155415597738){ref-type="table-fn"}^   Cell cycle; DNA replication
  KRT18 (Cytokeratin 18)                    1        Rb mAb          EPR1626        C-term (100 aa)                                      P05783          F1SGG1          93%                NEG                                                           Basic cytoskeletal
  KRT18 (Cytokeratin 18)                    5        IgG1            DC-10          unknown                                              P05783          F1SGG1          79%                NEG                                                           Basic cytoskeletal
  KRT19 (Cytokeratin 19)                    9        Goat poly       M-17           C-term (mouse)                                       P08727          F1S0J8          84%                NEG                                                           Basic cytoskeletal
  KRT20 (Cytokeratin 20)                    5        IgG2a           Ks 20.8        unknown                                              P35900          Q29218          75%                NEG                                                           Basic cytoskeletal
  KRT7 (Cytokeratin 7)                      1        Rb mAb          EPR1619Y       N-term (200 aa)                                      P08729          F1SGI7          57%                POS                                                           Basic cytoskeletal
  KRT7 (Cytokeratin 7)                      5        IgG1            OV-TL 12/30    unknown                                              P08729          F1SGI7          65%                POS                                                           Basic cytoskeletal
  MART1 (Melan A)                           5        IgG1            A103           unknown                                              Q16655          F1SMM1          73%                NEG                                                           Cytoplasmic; misc
  MCM5                                      9        IgG2b           E-10           aa 1-30                                              P33992          I3LR86          77%                POS                                                           Cell cycle; DNA replication
  Mel-18/PCGF2                              9        Goat poly       MEL-18 (C20)   C-term                                               P35226          F2Z5D1          99%                NEG                                                           Cell cycle; DNA replication
  MMR MLH1                                  5        IgG1            ES05           unknown (210 aa)                                     P40692          D3K5L8          91%                NEG                                                           Cell cycle; DNA replication
  MMR MSH2                                  11       IgG1            FE11           C-term                                               P43246          D3K5K3          95%                POS                                                           Cell cycle; DNA replication
  MMR MSH6                                  1        Rb mAb          EPR3945        C-term                                               P52701          I3LHZ9          91%                POS                                                           Cell cycle; DNA replication
  MMR PMS2                                  9        Rb poly         (C-20)         C-term (300 aa)                                      P54278          F1RFM9          78%                POS                                                           Cell cycle; DNA replication
  Mucin-2                                   9        IgG1            Ccp58          5 tandem repeats                                     N/A             N/A             N/A                NEG                                                           Cell--cell interaction
  Mucin-6                                   9        IgG1            CLH5           tandem repeats                                       N/A             N/A             N/A                NEG                                                           Cell--cell interaction
  MYC                                       1        Rb mAb          Y69            N-term                                               P01106          Q29031          94%                POS                                                           TF
  MYC                                       9        Rb poly         (N-262)        aa 1--262                                            P01106          Q29031          94%                POS                                                           TF
  Myeloperoxidase                           5        Rb poly                        unknown                                              P05164          K7GRV6          87%                POS                                                           Cytoplasmic; misc
  Napsin A                                  1        Rb mAb          EPR6257        aa 60--90                                            O96009          F1RH37          84%                NEG                                                           Cytoplasmic;misc
  NF Pool                                   5        IgG1            2F11           unknown                                              N/A             N/A             N/A                POS                                                           Basic cytoskeletal
  NKX2-1 (TTF-1)                            5        IgG1            8G7G3/1        unknown                                              P43699          F1SHK3          97%                POS                                                           TF
  Pax5                                      6        IgG1            1EW            unknown                                              Q02548          F1ST83          97%                NEG                                                           TF
  Pax5                                      11       Rb mAb          SP34           C-term (aa 251--261)                                 Q02548          F1ST83          63%                POS                                                           TF
  Perforin                                  11       IgG1            5B10           C-term (100 aa)                                      P14222          F1SUB6          75%                POS                                                           Cytoplasmic; misc
  Pmel 17 (HMB 45)                          5        IgG1            HMB45          unknown                                              P40967          Q4LE84          79%                NEG                                                           Cytoplasmic; misc
  PRDM1 / Blimp-1                           4        rat IgG2a       6D3            aa 255--395 (mouse)                                  O75626          F1RYP9          74%                NEG                                                           TF
  PRG Progesterone receptor                 5        IgG1            PGR 636        unknown                                              P06401          D0EWS6          85%                NEG                                                           TF
  Pro-opiomelanocortin (ACTH)               5        IgG1            02A3           aa 1--39 (N-term)                                    P01189          P01192          100%               NEG                                                           Cytoplasmic; misc
  Prolactin (PRL)                           5        Rb poly                        unknown                                              P01236          P01238          79%                POS                                                           Cytoplasmic; misc
  PSA                                       11       Rb poly                        unknown                                              P07288          P00752          59%                NEG                                                           Cytoplasmic; misc
  PTEN                                      4        Rb mAb          138G6          C-term                                               P60484          B8XSI6          99%                POS                                                           Receptor signaling
  S-100 alpha chain                         11       IgG2a           4C4.9          unknown                                              P23297          K7GQ84          73%                POS                                                           Cytoplasmic; misc
  S-100 alpha+beta                          5        Rb poly                        unknown                                              N/A             N/A             N/A                POS                                                           Cytoplasmic; misc
  Somatotropin (Growth hormone)             5        Rb poly                        unknown                                              P01241          P01248          68%                POS                                                           Cytoplasmic; misc
  Synaptophysin                             5        IgG1            DAK-SYNAP      C-term                                               P08247          F1RW46          94%                POS                                                           Cytoplasmic; misc
  TdT                                       5        Rb poly                        unknown                                              P04053          F1SBG2          86%                POS                                                           Cell cycle; DNA replication
  TFF3 (intestinal trefoil factor)          9        IgG1            H-425          unknown                                              Q07654          Q29183          80%                POS                                                           Cell--cell interaction
  Thyroglobulin                             11       Rb poly                        unknown                                              P01266          D1KKB3          74%                POS                                                           Cytoplasmic; misc
  Thyrotropin subunit beta (TSH)            11       IgG1            ZMTS2          unknown                                              P01222          P01224          89%                NEG                                                           Cytoplasmic; misc
  TP53                                      5        IgG2b           DO-7           aa 1--45                                             P04637          Q9TUB2          46%                POS                                                           Cell cycle; DNA replication
  TP53                                      12       IgG1            Pab 1801       aa 32--79                                            P04637          Q9TUB2          72%                NEG                                                           Cell cycle; DNA replication
  TP63                                      5        IgG2a           4A4            aa 1--205 (N-term)                                   Q9H3D4          I3LP4           99%                POS                                                           Cell cycle; DNA replication
  TP63                                      9        Rb poly         H-137          aa 15--151                                           Q9H3D4          I3LP4           98%                POS                                                           Cell cycle; DNA replication
  TP63 p40 (DN63)                           7        Rb poly                        aa 5--17                                             Q9H3D4-2        I3LPD4          99%                POS                                                           Cell cycle; DNA replication
  Vimentin                                  5        IgG1            V9             unknown                                              P08670          P02543          98%                POS                                                           Basic cytoskeletal
  vWF (von Willebrand Factor VIII)          5        Rb poly                        unknown                                              P04275          Q28833          75%                POS                                                           Cytoplasmic; misc
  WT1 Protein                               5        IgG1            6F-H2          aa 1--181                                            P19544          O62651          99%                POS^[\*](#table-fn1-0022155415597738){ref-type="table-fn"}^   TF
  ZEB1                                      10       Rb poly                        aa 498--627                                          P37275          F1RWD4          84%                POS                                                           TF

All antibodies listed are from mouse, except when differently noted \[rabbit (Rb); rat; goat\]. The epitope is listed if known. Note that the % similarity between human and pig is calculated for the shortest sequence known for the pig, for the full-length protein if the epitope is unknown. Ventral and diffuse prostate and testis were obtained from a bull. Under the "Tested" column: \*Differences in selected tissues; see text; ^\#^Non-specific staining, see text. ^¥^Different cell type stained. Abbreviations: poly, polyclonal; mAb, monoclonal antibody; N-term, N-terminal; C-term, C-terminal; POS, positive; NEG, negative; TF, transcription factor; Immun, immunity; misc, miscellaneous.

Human protein sequences and respective codes were obtained by querying UNIPROT (Universal Protein Resource) ([www.uniprot.org](http://www.uniprot.org)) (last accessed on March 24, 2015, tutorial at <http://www.uniprot.org/help/>). The sequence was queried in UNIPROT for the *Sus* taxa, the animal sequence aligned and inspected for the degree of similarity. In addition, the human sequence in FASTA format was aligned with BLAST (Basic Local Alignment Search Tool) (http://blast.ncbi.nlm.nih.gov) with default settings (last accessed on March 24, 2015, tutorial at [ftp://ftp.ncbi.nlm.nih.gov/pub/factsheets/HowTo_BLASTGuide.pdf](http://ftp://ftp.ncbi.nlm.nih.gov/pub/factsheets/HowTo_BLASTGuide.pdf)) for the taxa required (human, swine, rat, others). The sequence was blasted, filtered for the taxonomic species and aligned in order to obtain the percent identity. Sequence alignments of discrepant cases (antibody positive / low identity or vice versa) were reviewed and visually inspected. The term "partially conserved" will be used throughout for substitutions of amino acids between groups of strongly similar properties with scoring \>0.5 in the Gonnet PAM 250 matrix (see <http://www.uniprot.org/help/sequence-alignments>) ([@bibr39-0022155415597738]).

UniProtKB/Swiss-Prot database was preferred over UniProtKB/TrEMBL entries whenever available. Antibodies directed against multiple proteins (e.g., basic keratins) or carbohydrates were not considered for alignment.

The protein codes and the links are available as a supplementary Excel table (Supporting Information Table S1).

Epitope prediction modeling was used in selected cases with the IEDB Analysis Resource platform (<http://tools.immuneepitope.org/bcell/>) (last accessed on March 24, 2015, tutorial at <http://tools.immuneepitope.org/bcell/help/>). Human and porcine sequences were modeled with three algorithms (Emini surface accessibility scale, Kolaskar and Tongaonkar antigenicity scale and BepiPred Linear Epitope Prediction) in order to predict their epitope spatial disposition and accessibility; the latter was usually given a positive score on the y-axis. The data were imported in an Excel spreadsheet and a graph generated for the region of interest.

Virtual Whole-Slide Imaging {#section7-0022155415597738}
---------------------------

Stained slide images were acquired with an Aperio CS whole slide scanner (Leica Microsystems, Italy) at 20× and 40×. Individual single stain images in light microscopy were acquired with the ImageScope software (Aperio), optimized for contrast with Adobe Photoshop CS3 (Adobe Systems Incorporated, San Jose, CA), and mounted with Adobe Illustrator.

Results {#section8-0022155415597738}
=======

Overall Similarity and Impact on FFPE-Stained Samples {#section9-0022155415597738}
-----------------------------------------------------

The average similarity score (mean ± SD) for the full list of proteins that were evaluated with a panel of antibodies was 79.2% ± 17.4% (range, 20% CD45 to 100% actins, BCL2), and this percentage was conserved among antibodies routinely used for human diagnostics or reagents used for research projects. Similar percentages were reported in broader, genome-wide comparisons of human and pig sequences ([@bibr10-0022155415597738]).

Positive results, scored as specified, were recorded for 74/146 individual antibodies (50.7%). The positive-staining antibodies tended to cluster in the higher similarity group of targets ([Table 1](#table1-0022155415597738){ref-type="table"}).

The proteins against which the antibodies were raised were representative of a broad collection of targets, heterogeneous in function, and cellular and subcellular localization. In order to gain insight into whether there was any preferential reactivity by target, we subdivided the targets into broad categories, and each group was plotted according to the degree of similarity and the positive or negative result in FFPE ([Fig. 1](#fig1-0022155415597738){ref-type="fig"}). As reported previously ([@bibr18-0022155415597738]; [@bibr27-0022155415597738]), some groups diverged more than others during evolution (e.g., the immune-associated molecules); however, within each group, FFPE-reactive antibodies were related to a higher degree of similarity of the target ([Fig. 1](#fig1-0022155415597738){ref-type="fig"}). None of the secondary reagents used reacted with the swine tissue (not shown).

![Degree of similarity (human to porcine) versus FFPE staining using anti-human antibodies, categorized by protein class type. The human proteins against which antibodies have been raised are grouped by broad classes and plotted on a similarity scale. Within each class, darker symbols represents FFPE-staining antibodies, lighter ones non-staining antibodies.](10.1369_0022155415597738-fig1){#fig1-0022155415597738}

Specificity and Differential Reactivity for Human versus Porcine Tissues {#section10-0022155415597738}
------------------------------------------------------------------------

The correlation between the degree of similarity and the positive staining of fixed material ([Fig. 1](#fig1-0022155415597738){ref-type="fig"}) was accompanied by a generally highly conserved distribution of staining within the tissue at the cellular and subcellular levels (with few exceptions, see below) (see examples in Supporting information Fig. S1).

Four out of 74 positively staining antibodies (5.4%) either presented additional reactivity or lacked some stained cell types in the human-pig comparison. These are illustrated in [Figures 2](#fig2-0022155415597738){ref-type="fig"} through [4](#fig4-0022155415597738){ref-type="fig"}. These results were replicated on frozen sections (not shown).

![Differential reactivity for anti-human antibodies on swine tissue. (A, B) CD57 decorates follicular helper T cells in human tonsil (A), but not in porcine (B). Swine neural cells in Auerbach plexi are stained (inset). (C, D) Wilms' tumor 1 (WT1) stains the cytoplasm and nuclei (arrows) in the human kidney glomerulus (C) but only the nuclei are stained in the porcine kidney (D). Scale, 100 µm.](10.1369_0022155415597738-fig2){#fig2-0022155415597738}

![Heterogeneous staining patterns of anti-human antibodies on swine. (A) CD79a HM57 antibody stains scattered lymphocytes in the swine thymic medulla and all lymph nodal B cells (inset). (B) CD79a JCB11 antibody stains scattered lymphocytes in the swine thymic medulla but none in the lymph node (inset). (C) Ki-67 SP6 antibody stains the nuclei in an Auerbach neural plexus. (D, E) The same nuclei are unstained with anti-Ki-67 MIB 1 (D) and anti-MCM5 mouse antibody (E). (F, G) Ki-67 SP6 antibody weakly stains proliferating nuclei in porcine lymph node (F) but strongly in human tonsil (G). The C-terminal 250-aa sequence of human Ki-67 past the 16 repeated motifs (the immunogen for this monoclonal) has less than 40% similarity with the swine counterpart. Scale, 100 µm](10.1369_0022155415597738-fig3){#fig3-0022155415597738}

![CDKN1B (p27) antibodies stain opposite compartments in swine thymus. Porcine thymus (A, B and C), lymph node (D, E and F) and human tonsil (G, H and I) are stained with Ki-67 MIB 1 antibody (A, D and G), mouse anti-p27 (B, E and H) and rabbit anti-p27 (C, F and I). Note the opposite staining pattern of the mouse (B) and rabbit (C) reagents in the thymus. In the peripheral swine and human tissues, proliferating germinal center cells are unstained. Note the reversed staining intensity of both anti-p27 antibodies with porcine and human tissue. Double staining for Ki-67 and both anti-p27 antibodies showed that proliferating corticothymocytes were mutually exclusively labeled by the rabbit antibody and co-expressed CDKN1B with the mouse reagent; this co-expression is the expected distribution ([@bibr40-0022155415597738]). Scale, 100 µm](10.1369_0022155415597738-fig4){#fig4-0022155415597738}

Human Diagnostic IHC Control Use of Swine Tissue {#section11-0022155415597738}
------------------------------------------------

The pig may be a convenient source of positive external control for important diagnostic antibodies. We focused on targets important for diagnostics or therapy and difficult to standardize in QC schemes. About half of routinely used human diagnostic antibodies, including antibodies against ER, MYC, and Ki-67 (Supporting Information Fig. S1), were found to stain porcine FFPE tissue in an identical fashion to that of human tissue.

Next, we focused on antigens for which no normal tissue is currently used as a control. Anaplastic lymphoma kinase (ALK) protein is aberrantly expressed in hematolymphoid and solid tumor cancers, where genetic lesions cause overexpression ([@bibr46-0022155415597738]). Besides this, ALK has been shown to be expressed as a transcript in the human small intestine ([@bibr38-0022155415597738]; [@bibr55-0022155415597738]) and as a protein in the central nervous system and pons ([@bibr43-0022155415597738]). Public repositories of cDNA microarray data (BioGPS, <http://biogps.org>) (last accessed on October 2nd, 2014) report ALK expression in adrenal tissue (GeneAtlas U133A, gcrma; probe 208212_s\_at), in astrocytes (Primary Cell Atlas; probe 208212_s\_at) and heterogeneously at low levels in normal tissue, including the brain (Barcode on normal tissues).

We tested four different antibodies on three samples of human and one sample of swine small intestine; swine brain cortex, brainstem and cerebellum; and swine and bovine adrenal and failed to convincingly detect a specific signal for ALK. The reason why the ALK gene is transcribed, but not translated in normal adult tissues is unknown.

Similarly, we could not detect Her2 signal with three antibodies on pig breast and heart, which differs from that reported in the human ([@bibr23-0022155415597738]).

Epitope Mapping across Species {#section12-0022155415597738}
------------------------------

For 84 antibodies, the entire epitope has been mapped, the region identified in broader terms (C- or N-term) or the epitope can be inferred from the immunizing peptide: We considered this group as informative. Forty-four antibodies in this group recognized FFPE material, significantly for targets above a 60% similarity limit (40/70 ≥60% similar vs 4/14 \<60%; Chi square *p*= 1.66×10^-9^): This may represent a useful threshold to identify antibodies positive on FFPE material across species.

To gain insight into the amino acid substitutions within the epitope, we selected and examined a small group of antibodies whose epitope was relatively short (less than 24 aa; [Fig. 5](#fig5-0022155415597738){ref-type="fig"}). All of the non-identical sequences bearing conserved amino acid substitutions allowed binding of the human-specific antibodies. The CD8 epitope, which has numerous non-conserved amino acid substitutions ([Fig. 5](#fig5-0022155415597738){ref-type="fig"}) did not. Thus, the linear composition of an FFPE-proof epitope would allow changes in the sequence as long as these were completely or partially conserved.

![Epitope composition of six anti-human antibodies positive on swine formalin-fixed, paraffin-embedded (FFPE) material. Human (bold, top) and swine (light, bottom) sequence alignments for six protein epitopes are shown, with the antibody name at the top of each alignment. The position of the first amino acid in the human sequence is reported at the top left. The CD79a/JCB117 epitope has been split into two parts for graphic reasons. The only negatively staining antibody is CD8. Boxes highlight non-conserved substitutions. The legend is drawn from <http://www.uniprot.org/help/sequence-alignments> and <http://www.ebi.ac.uk/Tools/msa/clustalo/help/faq.html#24>. The color-coding sequence display was obtained by sequence alignment with Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>) (last accessed on March 24, 2015).](10.1369_0022155415597738-fig5){#fig5-0022155415597738}

Three antibodies positive on FFPE, for which the degree of similarity of the target was below 60% and thus expected to be negative, were further investigated, revealing possible cross-reactivity with proteins of the same biological function.

Keratin 7 has no direct homologous sequence in the pig; the nearest homology is to Keratin 75 (65% identity, 85% coverage), and the antibody labelled stratified epithelium but also mesothelial spleen-lining cells, consistent with keratin and analogous to that of human keratin 7 staining.

No porcine sequence close to the human Emerin could be found by BLAST search, despite the identical staining pattern. However, the human sequence has a low-coverage, 50% homology with a swine protein of similar nuclear membrane distribution, Inner nuclear membrane protein Man1, which itself is 93% similar to the human counterpart (Supporting Information Fig. S1); cross-reactivity with porcine Man1 may explain an identical immunostaining pattern.

The anti EMA (Muc-1) antibody we used (E29) is directed against an APDTRP epitope ([@bibr42-0022155415597738]), sensitive to glycosylation, and broadly distributed: It did not stain epithelial cells but positively identified sparse mononuclear cells. We classified it as positive; however, the type of antigen and the different tissue distribution in the pig suggest cross-reactivity via similar glycosylation of unrelated proteins.

No preferential representation of antibody type (polyclonal, rabbit monoclonal, mouse isotype) was noticed in the low-similarity binders in this group.

Among the antibodies negative on FFPE swine material, the CD20 L26 antibody is directed against a non-defined cytoplasmic portion of the MS4A1 protein; the three cytoplasmic portions of the protein, aa 1--56, 106--120 and 210--297 have, respectively, 75%, 60% and 81% similarity with swine MS4A1. Syndecan-1 (CD138), which shows 77% similarity in human and swine, has lower similarity (67%) in the aa 100--140 ectodomain, the region where the MI15 and B-B4 antibodies compete for binding ([@bibr13-0022155415597738]).

Antibodies staining human tissue may not recognize FFPE swine tissue if they are directed against a swine-restricted conformational epitope, which does not survive fixation and embedding, or because the epitope is missing altogether. Frozen sections from unfixed material should provide epitopes in a native form and would thereby allow an investigation as to why this group of reagents did not stain the routinely treated porcine material. To this end, 19 antibodies were tested: all were negative on FFPE material, 13 are directed at proteins with ≥75% similarity, and 3 were used as positive controls. These antibodies were tested on frozen sections from porcine small intestine (Supporting Information [Table 1](#table1-0022155415597738){ref-type="table"}). Only 3 antibodies of the 19 reacted positively: anti-Keratin 20, anti-cleaved PARP and anti-BCL6 clone PGB6p.

Epitope Projection Comparison between Human and Pig {#section13-0022155415597738}
---------------------------------------------------

Raw similarity percentage of the linear sequence of the porcine counterpart of the human epitope may not fully explain the binding of an antibody raised against another mammal. To further elucidate the conditions for binding of anti-human antibodies in pig tissue, 13 sequences identified by seven negative and five positively staining antibodies (as controls) were plotted and compared via the linear epitope prediction algorithms. The seven human-restricted sequences were chosen among the ones with 70% similarity or greater and shorter than 24 amino acids. Five out of the seven negative antibodies showed a noticeable difference in the conformation of the linear antigenic sequence in the pig with at least one modeling method ([Fig. 6](#fig6-0022155415597738){ref-type="fig"}). This was not observed for those antibodies that showed positive staining. Eleven known Ki-67 repeats in the human and in the pig were aligned, despite the partially conserved amino acid substitutions in the pig ([Fig. 5](#fig5-0022155415597738){ref-type="fig"}).

![Epitope prediction for 13 sequences from 7 negative and 5 positively staining antibodies. The individual amino acid (aa) score obtained with two algorithms (BepiPred: continuous line; Emini: dashed line) for each antibody target sequence is plotted on the y-axis for the human (black) and the pig (grey). For graphic clarity, two different scales (left and right) are occasionally produced in the same graph for each model. Arrow on the y-axis points to the 0 value above which the algorithm predicts the epitope (see Supporting Information for individual plots). Each amino acid position number is listed on the x-axis. The antibody and clone, the amino acid target human sequence and the staining results (+ or -) is listed at the top of each graph. Eleven Ki-67 repeats BepiPred scores were plotted by aligning the human and corresponding porcine dodecapeptide sequences, flanked by 13 amino acids and an empty space for graphic rendering. The open star marks the areas of noticeable differences between human and pig with at least one prediction model. The top two rows depict antibodies negative on FFPE and frozen swine material: in all but three (CD20 AA 106-120, CFTR, POMC), noticeable conformational changes in the pig may highlight an inaccessible sequence for the swine counterpart. The bottom two rows depict positively staining antibodies. A conformational change at the N-terminus of the CDKN1A and of the CD79a-JB117 epitope may not affect the binding to the remaining sequence. Notice that the known Ki-67 target sequence FKELF, at the center of each repeat, has a negative score with the BepiPred model. Scores obtained with the Kolaskar and Tongaonkar antigenicity scale are not shown because this has been found to be informative in few cases. Sequence gaps and terminal missing sequences with the Emini algorithm are shown. The CD20 aa 210--297 cytoplasmic sequence, which is not informative, is not shown.](10.1369_0022155415597738-fig6){#fig6-0022155415597738}

Because the prediction algorithms were unable to completely explain the failure of binding of some highly homologous epitopes, we re-examined the sequence details, starting with the anti-Ki-67 MIB 1 motif, recognized in humans, pig, dog, but not in rat or mouse ([@bibr15-0022155415597738]). The BepiPred algorithm successfully aligned the anti-Ki-67 motifs of human, pig and rat (Supporting Information Fig. S2). However, inspection of these sequences revealed a non-conserved amino acid sequence in the rat and mouse motifs that was not present in the corresponding porcine or dog motifs. This non-conserved amino acid substitution is close to the central core of the motif, and has been described as deleterious for this anti-Ki-67 antibody binding ([@bibr34-0022155415597738]). Therefore, amino acid changes known to alter the epitope recognition, as shown by peptide screening, may not be taken into account by the algorithms we have employed.

Re-examination of the amino acid alignments for an additional two highly homologous epitopes showed three non-conserved amino acid substitutions in the porcine Proopiomelanocortin (POMC) within the first 8 amino acids and one at aa 23. However, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which also did not show positive staining in the pig, had only one partially conserved substitution in the 10-amino acid epitope and an uninformative profile with the algorithms ([Fig. 6](#fig6-0022155415597738){ref-type="fig"} and Supporting Information).

Thus, besides non-conserved amino acid substitutions, there are other unknown factors which prevent the binding of human-specific antibodies to FFPE porcine epitopes and these cannot be entirely predicted by the available algorithms.

For 62 antibodies, no epitope specificity was available, they were directed against determinants shared by two or more proteins (e.g. acidic keratins), or they were simply polyclonal antibodies raised against pooled antigens (e.g. S-100). This group of reagents was therefore considered not informative for the epitope analysis part of the study, except for contributing to a trend for antibodies to stain preferably targets with higher similarity: only 3 out of the 23 antibodies that were positive on swine tissues were directed at targets less than 70% similar (Chi square *p*= 0.022).

Discussion {#section14-0022155415597738}
==========

By using naturally occurring amino acid variations introduced during evolution in related species, we have shown that antibodies tolerate partially conserved amino acid substitutions but fail to stain near-identical sequences that harbor subtle changes in epitope accessibility or show non-conserved substitutions. This understanding was possible to discern whenever a reasonably detailed information of the putative epitope was available. These results have been previously obtained only in vitro by synthetic peptide scanning ([@bibr25-0022155415597738]; [@bibr34-0022155415597738]). Starting with the reactivity on human FFPE material---considered the "default" status (i.e. 100% staining, 100% specific)---we generated a catalog of information that applies to each antibody applied to FFPE swine tissues in general and to FFPE-specific antibodies as a whole.

FFPE-Proof Antibodies Are Largely Interpretable by a Linear Epitope Model and Accommodate Epitope Variations {#section15-0022155415597738}
------------------------------------------------------------------------------------------------------------

Epitopes can be either linear or continuous. Because we applied epitope modeling, which assumes a linear composition, and we found that these models can interpret the tissue reactivity of the antibodies, our findings reinforce the assumption that these antibodies largely recognize linear epitopes in porcine and, by extension, human fixed and embedded tissue. The suggestion that FFPE antigens are linear has been made previously; they all survive FFPE processing, high heat during antigen retrieval (AR), and even 2-mercaptoethanol and SDS treatments ([@bibr24-0022155415597738]), and are therefore denaturation-resistant. FFPE-proof antibodies are generated against synthetic peptides ([@bibr31-0022155415597738]; [@bibr37-0022155415597738]) or denatured antigens ([@bibr57-0022155415597738]), another suggestion that they detect linear continuous epitopes, rather that conformation-dependent, discontinuous ones ([@bibr1-0022155415597738]; [@bibr21-0022155415597738]; [@bibr33-0022155415597738]).

For some antibodies, the immunogenic sequence is known. Antibodies in this group bound targets with an overall similarity as low as 60%. This suggests that antibodies selected to react on FFPE tissue allow quite some variation in the sequence composition of the target, taking into account that the score derives from a matrix calculation for individual amino acid substitutions, not the simple identical/non-identical ratio.

Some epitopes, perfectly aligned according to the algorithms and highly similar to the human, were not detected in fixed or frozen swine material: We do not have a good explanation for this observation. Alternative splicing may be one explanation, but the pig genomic database does not have enough information to further investigate this possibility. Post-transcriptional protein modifications or complexes with other proteins may be a cause; the mosaic staining by the CD79a antibody JCB117 may be a good example.

One last additional reason for the differential reactivities of the antibodies on human and swine FFPE material may be the idiosyncrasy of the paratope for a unique binding milieu, going undetected by still imprecise modeling tools ([@bibr41-0022155415597738]). Part of the required binding sequences may be located on adjacent protein loops, as shown for some therapeutic antibodies ([@bibr11-0022155415597738]); swine-specific changes in these sequences may prevent FFPE staining.

For these reasons, it will be impossible to predict whether an anti-human antibody will bind a related mammal, except by making an educated guess by epitope sequence similarity and staining the tissue.

We ruled out a suboptimal AR condition for the negative staining, because some of the highly similar (\>80%) protein targets such as CD34, Cytokeratins, Mucin, Napsin A, Progesterone Receptor, were negative despite being abundantly expressed and detectable even without AR.

The epitope sequences did survive fixation, embedding and AR, which reverses many of the formalin-induced chemical bonds that prevent antibody access to the epitope. Not all bonds are resolved; among these may be bonds further stabilized by dehydration ([@bibr22-0022155415597738]), as shown by human FFPE-proof targets detected on frozen section only in the pig. Interestingly, only one out of three antibodies raised against the same N-terminal half of the BCL6 protein was fixation-sensitive in the pig, further suggesting that the stable, AR-insensitive bond had a local effect but did not modify the neighboring binding sites or the overall antigenic sequence conformation of porcine N-terminal BCL6, another hint at the linearity of the FFPE epitopes.

Porcine Tissue Can Be a Source of Reference FFPE Material for Human Quality Control {#section16-0022155415597738}
-----------------------------------------------------------------------------------

None of the 146 antibodies tested yielded any sort of "background" or non-specific staining; only four of the 74 that did stain resulted in a tissue or cellular staining pattern that could be classified as substantially different from that in human tissue, namely EMA, WT1, CD57 and the Ki-67 antibody SP6. The specificity of WT1 cytoplasmic staining in human endothelial cells is discussed ([@bibr8-0022155415597738]), and was absent in the swine tissue, suggesting that the cytoplasmic staining is spurious. Non-specific (cytoplasmic) staining of Ki-67 antibodies in non-human cells has been described previously ([@bibr17-0022155415597738]).

For the vast majority of positively staining antibodies, swine tissue provided a histological and immunohistochemical staining identical to human tissue.

Swine tissue from abattoirs is thus a human-like material that can be used as an external control tissue and is nearly ubiquitous, cheap, freely exchangeable and free of the ethical constraints that limit the use of human tissue. This is most important for noble organs (brain, brainstem, heart) or small tissues (endocrine glands, ganglia) that are not commonly available in sufficient quantity as a healthy human control tissue. In addition, swine tissues may be used to standardize the detection of therapy-modifying targets (estrogen receptors ([@bibr49-0022155415597738]), MYC ([@bibr32-0022155415597738]), for example) in daily practice for antibodies proven to stain the pig.

Antibodies directed against mutated proteins (V600E BRAF ([@bibr6-0022155415597738]), R132H IDH1 ([@bibr7-0022155415597738])), pathogens (EBV, KSHV, TB, among others) or proteins overexpressed because of a tumor-specific genetic modification (e.g., promoter swapping by chromosomal translocation for ALK or gene amplification for Her2) still need human pathological tissue or cell blocks from cultured cell lines. For some antigens that are structurally more divergent during evolution (CD30, immune receptors ([@bibr10-0022155415597738])), either different taxa may be investigated or human tissue still may be needed.

A minority of antibodies recognizing the FFPE porcine tissue showed a substantial differential reactivity, justifying in those few cases a concern about the monospecificity of the antibody, which is worth further investigation. To the contrary, the specificity of the vast majority of the remaining reagents currently used for diagnosis on human samples, accommodating epitope variations at least 50% of the time, is an encouraging finding; these antibodies may be used on occasionally heavily mutated targets, such as melanoma and lung cancer ([@bibr47-0022155415597738]), because of non-synonymous mutations. As we add more antibodies tested on both species, we keep finding reliable antibodies and, rarely, suspicious, unexpected staining (data not shown).

Not every manufacturer details the specificity of the epitope against which the antibody is directed, often because it is considered proprietary information, despite abundant evidence that, for a single immunogen, there are a variety of unique individual epitopes, each one recognized by a monoclonal antibody or an antiserum ([@bibr25-0022155415597738]). We have shown, however, that the availability of that information may help in choosing one reagent over another for the use across species or for validation studies ([@bibr3-0022155415597738]; [@bibr50-0022155415597738]). Ideally, the datasheet accompanying an antibody vial should carry the complete immunogen sequence and information on whether the antibody recognizes FFPE mammalian tissue other than human, preferably obtainable from abattoirs.
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